Bausch Health (BHC)
(Delayed Data from NYSE)
$7.19 USD
-0.10 (-1.37%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $7.20 +0.01 (0.14%) 6:26 PM ET
3-Hold of 5 3
A Value C Growth B Momentum A VGM
Price, Consensus and EPS Surprise
BHC 7.19 -0.10(-1.37%)
Will BHC be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BHC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BHC
Bausch (BHC) Q1 Earnings and Revenues Miss, Shares Fall
Bausch Health (BHC) Q1 Earnings and Revenues Miss Estimates
BHC: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Bausch (BHC) Rating Upgrade to Buy
Will Bausch (BHC) Beat Estimates Again in Its Next Earnings Report?
Bausch (BHC) Starts Litigation Against Amneal for Xifaxan
Other News for BHC
Carl Icahn's Firm Expands Grip on Icahn Enterprises LP Holding
Carl Icahn's Strategic Acquisition in Icahn Enterprises LP
Bausch Health call volume above normal and directionally bullish
Bausch files patent suit against Norwich over generic Xifaxan
Bausch Health Defends XIFAXAN® Patent Again